The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients

Surgery Today

Volumn 44, Issue 9, 2014, Pages 1692-1701

  Kanda, Mitsuro ^a   Fujii, Tsutomu ^a   Takami, Hideki ^a   Suenaga, Masaya ^a   Inokawa, Yoshikuni ^a   Yamada, Suguru ^a   Nakayama, Goro ^a   Sugimoto, Hiroyuki ^a   Koike, Masahiko ^a   Nomoto, Shuji ^a   Kodera, Yasuhiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CA19 9; Pancreatic cancer; Prognostic factor; Tumor marker

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PANCREATIC CANCER ASSOCIATED ANTIGEN; S PANCREAS 1 ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; ARTICLE; ATTRIBUTABLE RISK; CANCER MORTALITY; CANCER PROGNOSIS; FEMALE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; POSTOPERATIVE PERIOD; PREDICTION; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; RECEIVER OPERATING CHARACTERISTIC; SERUM; SURVIVAL RATE; UNIVARIATE ANALYSIS; ADULT; BLOOD; CARCINOMA, PANCREATIC DUCTAL; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PROGNOSIS; RISK; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 84906351265     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-013-0752-9     Document Type: Article

References (37)

1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-20.
2. Kanda M, Fujii T, Sahin TT, Kanzaki A, Nagai S, Yamada S, et al. Invasion of the splenic artery is a crucial prognostic factor in carcinoma of the body and tail of the pancreas. Ann Surg. 2010;251:483-7.
3. Ellison LF, Wilkins K. An update on cancer survival. Health Rep. 2010;21:55-60.
4. Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an update. Dig Dis. 2010;28:645-56.
5. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-79.
6. Kanda M, Fujii T, Nagai S, Kodera Y, Kanzaki A, Sahin TT, et al. Pattern of lymph node metastasis spread in pancreatic cancer. Pancreas. 2011;40:951-5.
7. Trouilloud I, Dubreuil O, Boussaha T, Lepère C, Landi B, Zaanan A, et al. Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Clin Res Hepatol Gastroenterol. 2011;35:364-74.
8. Willett CG, Czito BG, Bendell JC, Ryan DP. Locally advanced pancreatic cancer. J Clin Oncol. 2005;23:4538-44. (Pubitemid 46196584)
9. Katz MHG, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16:836-7.
10. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-10. (Pubitemid 38339364)
11. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28:1645-51.
12. Yamada S, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, et al. Surgical results of pancreatoduodenectomy in elderly patients. Surg Today. 2012;42:857-62.
13. Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2011;98:268-74.
14. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma, a population based, linked database analysis of 396 patients. Ann Surg. 2003;237:74-85. (Pubitemid 36622320)
15. Moon HJ, An JY, Heo JS, Choi SH, Joh JW, Kim YI. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas. 2006;32:37-43.
16. Nakao A, Kanzaki A, Fujii T, Kodera Y, Yamada S, Sugimoto H, et al. Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg. 2012;255:103-8.
17. Lamerz R. Role of tumor markers, cytogenetics. Ann Oncol. 1999;10:145.
18. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21:441-7.
19. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer. 1994;69:515-9. (Pubitemid 24076471)
20. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009;6:e1000046.
21. Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jørgensen J, Wolf H, et al. Reference values and biological variation for tumor marker CA19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem. 1999;45:54-61. (Pubitemid 29036385)
22. Tessler DA, Catanzaro A, Velanovich V, Havstad S, Goel S. Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis. Am J Surg. 2006;191:191-7. (Pubitemid 43151265)
23. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez- delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897-902. (Pubitemid 46630592)
24. Hata S, Sakamoto Y, Yamamoto Y, Nara S, Esaki M, Shimada K, et al. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2012;19:636-41.
25. International Union Against Cancer. TNM classification of malignant tumors. 7th ed. New York: Wiley-Blackwell; 2009.
26. Szklo M, Nieto J. Epidemiology: beyond the basics. 2nd ed. Massachusetts: Jones and Bartlett Publishers; 2006.
27. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg. 2003;138:951-5.
28. Maithel SK, Maloney S, Winston C, Gönen M, D'Angelica MI, Dematteo RP, et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2008;15:3512-20.
29. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983;43:5489.
30. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9:132-8.
31. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004;11:644-9. (Pubitemid 40486698)
32. Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol. 2008;14:3750-3.
33. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501.
34. Duraker N, Hot S, Polat Y, Höbek A, Gençler N, Urhan N. CEA, CA19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 2007;95:142-7. (Pubitemid 46238983)
35. Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, et al. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent 3-dimensional conformal radiation, surgery and postopertive liver perfusion chemotherapy for T3-pancretic cancer. Ann Surg. 2009;250:88-95.
36. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496-502.
37. Heinrich S, Pestalozzi BC, Schäfer M, Weber A, Bauerfeind P, Knuth A, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:2526-31.